Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 13/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 13/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444512 | 0.92 | HDAC6 (0.55) | HDAC6TAS1R3TAS1R1HDAC3HDAC1 | |
| SCHEMBL4256678 | 0.82 | HDAC6 (0.49) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4250954 | 0.80 | TAS1R3 (0.66) | HDAC6TAS1R3TAS1R1HDAC3HDAC1 | |
| SCHEMBL4257464 | 0.80 | PIN1 (0.47) | TAS1R3TAS1R1HDAC3HDAC1HDAC2 | |
| SCHEMBL4251053 | 0.79 | TAS1R3 (0.62) | TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL4247496 | 0.79 | TAS1R3 (0.57) | HDAC6TAS1R3TAS1R1HDAC3HDAC1 | |
| SCHEMBL4252933 | 0.76 | TAS1R3 (0.48) | HDAC6TAS1R3TAS1R1HDAC3HDAC1 | |
| SCHEMBL4252461 | 0.75 | TAS1R3 (0.50) | TAS1R3TAS1R1 | |
| SCHEMBL4255578 | 0.74 | TAS1R3 (0.49) | TAS1R3TAS1R1 | |
| SCHEMBL4250157 | 0.73 | TAS1R3 (0.41) | HDAC6TAS1R3TAS1R1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC8, HDAC3 | HDAC6 11/4885TAS1R3 3722/4885TAS1R1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.